NASDAQ · IDYA
Healthcare · Biotechnology
$38.84
Down-$1.02 (-2.56%)
Updated Sep 9, 2026, 2:27 AM
SID Score
6.3/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
IDYA closed at $39.86 after 19 trading sessions, up 8.20% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $39.55 | $40.0699 | $39.42 | $39.86 | 448.01K |
| Sep 3, 2026 | $40.41 | $40.665 | $39.56 | $39.97 | 567.9K |
| Sep 2, 2026 | $40.20 | $41.48 | $39.58 | $40.17 | 765.29K |
| Sep 1, 2026 | $39.85 | $40.20 | $38.90 | $39.95 | 587.8K |
| Aug 31, 2026 | $39.74 | $40.32 | $39.43 | $40.10 | 977.81K |
| Aug 28, 2026 | $41.14 | $41.635 | $40.04 | $40.11 | 714.07K |
| Aug 27, 2026 | $41.63 | $42.095 | $40.965 | $41.77 | 534.41K |
| Aug 26, 2026 | $42.26 | $42.325 | $41.09 | $41.58 | 724.9K |
| Aug 25, 2026 | $40.88 | $42.68 | $40.06 | $42.48 | 1.02M |
| Aug 24, 2026 | $39.73 | $40.46 | $39.12 | $40.04 | 786.77K |
| Aug 21, 2026 | $39.34 | $40.56 | $39.31 | $39.67 | 860.57K |
| Aug 20, 2026 | $38.24 | $39.28 | $37.8894 | $39.11 | 1.63M |
| Aug 19, 2026 | $39.01 | $39.2995 | $37.84 | $38.87 | 931.92K |
| Aug 18, 2026 | $36.41 | $37.975 | $36.3883 | $37.93 | 629.49K |
| Aug 17, 2026 | $36.04 | $36.82 | $35.80 | $36.54 | 427.84K |
| Aug 14, 2026 | $36.68 | $36.68 | $35.66 | $36.30 | 435.26K |
| Aug 13, 2026 | $36.915 | $37.63 | $36.615 | $36.68 | 466.19K |
| Aug 12, 2026 | $36.75 | $37.20 | $36.46 | $36.96 | 508.83K |
| Aug 11, 2026 | $36.48 | $37.3525 | $36.025 | $36.84 | 488.6K |
The latest Smart Investors Daily articles mentioning IDYA.
IDYA research
Company profile and research snapshot.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 1, 2026 | Citizens | Market Outperform | — |
| Aug 5, 2026 | Wedbush | Outperform | — |
| Aug 5, 2026 | Truist Securities | Buy | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
| Jul 7, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 1, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and participation in September 2026 investor conferences.
Benzinga · Sep 1, 2026
Citizens analyst Silvan Turkcan reiterates IDEAYA Biosciences (NASDAQ:IDYA) with a Market Outperform and maintains $42 price target.
Benzinga · Sep 1, 2026
IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced its upcoming Investor R&D Day in London and
Yahoo · Aug 31, 2026
IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced a successful FDA Type C meeting to determine the Phase 3 registrational trial design for IDE849, a potential best-in-class delta-like ligand 3 (DLL3)-targeting Topo-I-payload antibody drug conjugate (ADC), in extensive stage small cell lung cancer (ES-SCLC). IDEAYA is targeting to initiate the Phase 3 registrational study in ES-SCLC by year
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IDYA.
